Abstract:Adi Yugatama, 1, 2, &ast Ya-Lin Huang, 1, &ast Ming-Jen Hsu, 3 Jia-Pei Lin, 1 Fang-Ching Chao, 4 Jenny KW Lam, 5 Chien-Ming Hsieh 1, 5, 6 1 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan; 2 Department of Pharmacy, Sebelas Maret University, Surakarta, 57126, Indonesia; 3 Department of Pharmacology, Taipei Medical University, Taipei, 11031, Taiwan; 4 CNRS UMR 8612, Institut Galien Paris-Saclay, Université Paris-Saclay, Orsay, 91400, France; 5 Department of Pharmaceutics, School of Pharmacy, University College, London, WC1N 1AX, UK; 6 Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan &astThese authors contributed equally to this work Correspondence: Jenny KW Lam, Department of Pharmaceutics, School of Pharmacy, University College London, 29– 39 Brunswick Square, London, WC1N 1AX, UK, Email Chien-Ming Hsieh, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan, Email Background: Gemcitabine (GEM) faces challenges of poor oral bioavailability and extensive first-pass metabolism. Currently, only injectable formulations are available for clinical use. Hence, there is an urgent demand for the development of advanced, efficacious, and user-friendly dosage forms to maintain its status as the primary treatment for pancreatic ductal adenocarcinoma (PDAC). Nanogels (NGs) offer a novel oral drug delivery system, ideal for hydrophilic compounds like GEM. This study aims to develop NGs tailored for GEM delivery, with the goal of enhancing cellular uptake and gastrointestinal permeability for improved administration in PDAC patients. Methods: We developed cross-linked NGs via photopolymerization of methacryloyl for drug delivery of GEM. We reveal characterization, cytotoxicity, and cellular uptake studies in Caco-2 and MIA PaCa-2 cells. In addition, studies of in vitro permeability and pharmacokinetics were carried out to evaluate the bioavailability of the drug. Results: Our results show NGs, formed via photopolymerization of methacryloyl, had a spherical shape with a size of 233.91± 7.75 nm. Gemcitabine-loaded NGs (NGs-GEM) with 5% GelMA exhibited efficient drug loading (particle size: 244.07± 19.52 nm). In vitro drug release from NGs-GEM was slower at pH 1.2 than pH 6.8. Cellular uptake studies indicated significantly enhanced uptake in both MIA PaCa-2 and Caco-2 cells. While there was no significant difference in GEM's AUC and Cmax between NGs-GEM and free-GEM groups, NGs-GEM showed markedly lower dFdU content (10.07 hr∙μg/mL) compared to oral free-GEM (19.04 hr∙μg/mL) after oral administration (p< 0.01), highlighting NGs' efficacy in impeding rapid drug metabolism and enhancing retention. Conclusion: In summary, NGs enhance cellular uptake, inhibit rapid metabolic degradation of GEM, and prolong retention after oral administration. These findings suggest NGs-GEM as a promising candidate for clinical use in oral pancreatic cancer therapy. Keywords: oral delivery, nanogel, gemcitabine, pancreatic cancer Pancreatic cancer remains one of the top ten causes of cancer deaths, which is possibly due to its late stage of recognition. In 2020, it was estimated that 495,773 new cases of pancreatic cancer, and the incidence varied by region and population. 1 Gemcitabine (GEM) is a first-line drug for metastatic pancreatic cancer approved by the Food and Drug Administration (FDA). GEM has demonstrated tremendous efficacy along with clinical benefits over 5-fluorouracil for more than 20 years. 2 The drug has demonstrated wide-spectrum application in various solid tumors. Despite exhibiting considerable therapeutic efficacy, GEM is subject to various constraints, such as a relatively brief plasma half-life, as well as limited permeability. 3–5 The brief duration of serum half-life can be ascribed to the swift and extensive process of deamination of GEM by cytidine deaminase (CDA), which is present in several tissues such as blood, liver, and kidneys. 6,7 Cytidine deaminase enzymatically converts GEM into its inactive metabolite, known as 2',2'-difluoro-2'-deoxyuridine (dFdU), which is then eliminated through urinary excretion. Consequently, the administration of GEM necessitates regular dosing intervals in order to sustain a therapeutic concentration of the drug within the systemic circulation. 7 In addition, it is notable that GEM is frequently administered to patients through the intravenous (IV) route, leading to an increased risk of venou -Abstract Truncated-

Poly (L-Glutamic Acid)-G-methoxy Poly (ethylene Glycol)-Gemcitabine Conjugate Improves the Anticancer Efficacy of Gemcitabine.

Improving plasma stability and antitumor effect of gemcitabine via PEGylated liposome prepared by active drug loading

Antitumor Gemcitabine Conjugated Micelles from Amphiphilic Comb-Like Random Copolymers

In vitro and in vivo anti-tumor effects of gemcitabine loaded with a new drug delivery system

Stimuli-Sensitive Biodegradable and Amphiphilic Block Copolymer-Gemcitabine Conjugates Self-Assemble into a Nanoscale Vehicle for Cancer Therapy.

Lipid-like gemcitabine diester-loaded liposomes for improved chemotherapy of pancreatic cancer

CD44-targeting Hydrophobic Phosphorylated Gemcitabine Prodrug Nanotherapeutics Augment Lung Cancer Therapy.

Comparative pharmacokinetic study of PEGylated gemcitabine and gemcitabine in rats by LC-MS/MS coupled with pre-column derivatization and MSALL technique.

Sustained release of lipophilic gemcitabine from an injectable polymeric hydrogel for synergistically enhancing tumor chemoradiotherapy

A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability

Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer

Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations

Synthesis and Characterization of Saccharide‐functionalized Polymer–gemcitabine Conjugates Based on Chemoenzymatic Selective Strategy

Co-delivery of Gemcitabine and Cisplatin Via Poly (L-Glutamic Acid)-G-methoxy Poly (ethylene Glycol) Micelle to Improve the in Vivo Stability and Antitumor Effect

Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: in Vitro and in Vivo Evaluation

Polygemcitabine Nanogels with Accelerated Drug Activation for Cancer Therapy.

Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells

Enhanced Anticancer Activity of Gemcitabine Coupling with Conjugated Linoleic Acid Against Human Breast Cancer in Vitro and in Vivo.

A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor

Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.